Eden Biodesign Assists Momotaro-Gene, Inc. to Commence Human Clinical Trials Less Than 12 Months After Being Engaged to Produce a Recombinant Adenovirus Vector from a New Cell Line

LIVERPOOL, England & OKAYAMA, Japan--(BUSINESS WIRE)--Eden Biodesign Ltd. and Momotaro-Gene, Inc. today announced the success of a collaborative global project that demonstrated Eden’s capabilities to work quickly to develop an adenoviral manufacturing process providing Momotaro-Gene with drug substance and vialed drug product ready for their clinical trial within 12 months. Momotaro-Gene, Inc. already cleared its first IND (Investigational New Drug) application with this drug product to the FDA and expects to start its First-In-Man clinical trial at Mt. Sinai Hospital, USA, this month.